BMO Capital analyst Joanne Wuensch maintained a Buy rating on Nevro (NVRO) today and set a price target of $67. The company’s shares opened today at $62.05.
According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 13.7% and a 74.9% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Tandem Diabetes Care Inc, Boston Scientific Corp, and Baxter International.
Currently, the analyst consensus on Nevro is a Moderate Buy with an average price target of $64.83, which is a 4.5% upside from current levels. In a report issued on March 20, Merrill Lynch also upgraded the stock to Buy with a $70 price target.
See today’s analyst top recommended stocks >>
Based on Nevro’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $9.61 million. In comparison, last year the company had a GAAP net loss of $4.31 million.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVRO in relation to earlier this year. Earlier this month, Doug Alleavitch, the VP, Quality of NVRO bought 1,031 shares for a total of $43,611.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
